Slingshot members are tracking this event:

Bristol-Myers Squibb (BMY) Presents Data From Phase 3 CheckMate -026 Evaluating Opdivo Monotherapy Versus Chemotherapy in First-Line Treatment of Broad PD-L1 Positive Advanced Lung Cancer

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 09, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3, Checkmate -026, Opdivo, Monotherapy, Chemotherapy, First-line, Broad Pd-l1 Positive, Advanced Lung Cancer